Janssen, Bayer Must Face Third Bellwether In Xarelto MDL
Law360, New York (July 24, 2017, 8:49 PM EDT) -- A Louisiana federal judge on Friday refused to grant Johnson & Johnson unit Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. a quick win in a patient’s suit accusing them of not warning about the possibility of dangerous internal bleeding associated with the blood thinner Xarelto, allowing the third bellwether trial in the multidistrict litigation to move forward.
In the request for partial summary judgment that U.S. District Judge Eldon E. Fallon denied, Janssen and Bayer argued that they didn’t have the authority to change the drug’s label and that state claims brought by Dora Mingo were preempted by federal law....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!